Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy

Table 5 Univariate and multivariate analyses of the probability of predicting DVT incidence in cancer patients undergoing chemotherapy

Covariate	Univariate analysis		Multivariate analysis^a
Covariate	RR (95% CI)	P	RR (95% CI)	P
Age ≥ 55 years	1.50 (0.13–16.32)	0.739
Male sex	2.00 (0.29–13.51)	0.477
Type of cancer, low risk vs. high/very high risk	2.53 (0.37–17.24)	0.341
Cancer stage, localized vs. advanced/metastasis	0.88 (0.13–6.00)	0.904
Chemotherapy regimen
Cisplatin/carboplatin-based	3.27 (0.47–22.46)	0.228	0.454 (0.208–26.68)	0.704
Fluorouracil-based	4.77 (0.48–46.90)	0.182	1.309 (0.606–17.14)	0.456
Bevacizumab	1.50 (0.13–16.32)	0.739
Anthracycline	2.66 (0.22–32.17)	0.440
Use of steroids	3.20 (0.24–42.18)	0.377
Group O blood type	0.77 (0.77–7.71)	0.825
D-dimer ≥2320 ng/mL (75th percentile)	2.55 (0.52–12.48)	0.242
D-dimer ≥4622.4 ng/mL (90th percentile)	3.57 (0.707–18.04)	0.123	1.00 (0.99–2.01)	0.900
High Khorana risk score	8.07 (0.84–77.1)	0.07	0.537 (0.121–13.65)	0.537
Prechemotherapy sP-selectin ≥105.5 ng/mL	11.67 (2.22–61.27)	0.004	1.02 (0.98–11.05)	0.260
Prechemotherapy vWF:Ag ≥ 2.35 IU/mL	7.50 (1.53–36.71)	0.013	3.80 (1.15–12.48)	0.028
Prechemotherapy ADAMTS-13 ≤ 1.03 IU/mL	13.5 (1.31–38.65)	0.029	2.67 (1.22–23.82)	0.005

NOTE: ^aIn the multivariate model, the area under the ROC curve = 0.873 (95% CI 0.675–0.925, p = 0.004). Hosmer-Lemeshow goodness-of-fit test: X² = 3.349, df = 8, p = 0.138. Null hypothesis = 0.5

ISSN: 1477-9560